Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing that Janssen Pharmaceutical’s (J&J) Stelara (ustekinumab) and MSD’s Januvia (sitagliptin) will face price cuts due to the return of the…
To read the full story
Related Article
- More than Half of Drug Makers’ Top 5 Meds See Flat or Positive Revisions: Poll
March 12, 2025
- Two-Thirds of Drug Makers Discontent with FY2025 Price Revision: Survey
March 11, 2025
- Drug Makers Weigh Withdrawal of Unprofitable Drugs, Generic and Innovative Players Alike: Poll
March 11, 2025
- Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
March 10, 2025
- Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision
March 10, 2025
- 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums
January 16, 2025
- Deferred PMP Cuts Likely to Batter Stelara; 7 Drugs Subject to Rule after LOE
December 24, 2024
REGULATORY
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
- PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
- Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…